Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00599326 · ClinicalTrials.gov registry record · Phase 3
Pilot Trial of Deferasirox in the Treatment of Porphyria Cutanea Tarda
A Phase 3 study, sponsored by University of Texas Southwestern Medical Center.
- Completed
- Registry status
- Phase 3
- Development phase
- 10
- Enrollment target
NCT00599326 is a Phase 3 study that has completed, run by University of Texas Southwestern Medical Center. The registered enrollment target is 10 participants.
The verdict
NCT00599326, a Phase 3 study, has completed, sponsored by University of Texas Southwestern Medical Center.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 10 participants
- Enrollment target
Study Summary
To determine the efficacy and tolerability of deferasirox in the treatment of Porphyria Cutanea Tarda. Primary objective - the elimination of all blistering within 6 months of treatment. Secondary objective - decrease in total body iron levels.
Interventions
- DRUG Deferasirox
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2008-01 |
| Est. Completion | 2010-04 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00599326
The ClinicalTrials.gov registry entry for NCT00599326 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 10 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Texas Southwestern Medical Center, which has 837 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Deferasirox is the first listed.
NCT00599326 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00599326 about?
NCT00599326 is a clinical study titled "Pilot Trial of Deferasirox in the Treatment of Porphyria Cutanea Tarda". To determine the efficacy and tolerability of deferasirox in the treatment of Porphyria Cutanea Tarda. Primary objective - the elimination of all blistering within 6 months of treatment. Secondary objective - decrease in total body iron levels.
What is the current status of trial NCT00599326?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 10 participants. The study started on 2008-01. Estimated completion is 2010-04.
What interventions are being tested in trial NCT00599326?
The interventions under investigation include: Deferasirox (DRUG).
Who is sponsoring clinical trial NCT00599326?
This trial is sponsored by University of Texas Southwestern Medical Center, which has 837 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.